Home » RedHill Biopharma’s Yeliva Gets $300k COVID-19 Grant from Pennsylvania
RedHill Biopharma’s Yeliva Gets $300k COVID-19 Grant from Pennsylvania
Redhill Biopharma’s Yeliva (opaganib) was chosen for a $300,000 grant from the state of Pennsylvania’s COVID-19 Vaccines, Treatments and Therapies (CV-VTT) Program.
The grant covers preclinical research that will examine the drug’s ability to suppress the extent and duration of COVID-19-related acute respiratory distress syndrome. It was awarded to RedHill’s partner, Apogee Biotechnology, which will conduct the research using the state funding.
Yeliva is currently in mid-to-late stage testing globally for hospitalized patients with severe COVID-19 pneumonia who require supplemental oxygen.
Upcoming Events
-
21Oct